Matches in Nanopublications for { ?s ?p "DDI between Dihydroergotamine and Telaprevir - Telaprevir increases levels by affecting CYP3A4 metabolism. Concomitant therapy is contraindicated. [drugbank_resource:DB00320_DB05521]"@en ?g. }
Showing items 1 to 1 of
1
with 100 items per page.